Editorials |
From the Center for Cardiovascular Research, University of Rochester, Rochester, NY.
Correspondence to Bradford C. Berk, MD, PhD, Cardiology Unit, Box 679, 601 Elmwood Ave, Rochester, NY 14642. E-mail Bradford_Berk{at}urmc.rochester.edu
Key Words: ischemia/reperfusion mitogen-activated protein kinase apoptosis cardiomyocyte
| Introduction |
|---|
|
|
|---|
Myocyte loss during the acute stage of myocardial infarction involves both apoptotic and necrotic cell death.2 3 4 Therefore, it is reasonable to think that the balance of cell survival and death is critical during the pathological evolution of postischemic cardiac dysfunction. Recently, many scientists seeking to elucidate the intricate relationship between signal transduction and this balance of survival and death in ischemic myocardium have focused on MAP kinases.
| MAP Kinases |
|---|
|
|
|---|
and p38ß isoforms are found in the
heart.5 Recently, a fourth MAP kinase member, big MAPK-1
(BMK1, also known as ERK5), has been identified in cardiac tissue
(Figure
|
| JNK and p38: Proapoptotic Bad Guys? |
|---|
|
|
|---|
The role of p38 in myocyte apoptosis is puzzling because p38
can also mediate cardiac hypertrophy. One of the ways that
p38 can induce apoptosis is through its effect on cyclin D1
expression during cell cycle. It has been demonstrated that the
coexpression of MKK3 along with p38 inhibits mitogen-induced cyclin D1
expression.10 However, evidence implies a protective role
for p38 during ischemia: p38 phosphorylates
MAPKAPK2, which in turn phosphorylates
HSP27.11 Activation of this pathway is cytoprotective, and
overexpression of HSP27 confers protection against ischemia in
myocytes.12 13 Protection by ischemic
preconditioning also appears to be dependent on p38
activation,14 and direct activation of p38 and JNK by
anisomycin is cardioprotective.14 Activation of different
p38 isoforms may explain these findings; p38
may be
proapoptotic, whereas p38ß may be antiapoptotic in
rat neonatal ventricular myocytes.15 In
summary, the current data for p38 and JNK suggest multiple roles in
ischemia, reperfusion, preconditioning, and
hypertrophy. Defining their precise roles and interaction
will require cardiac-specific p38 and JNK knockout mice.
| ERK1 and BMK1: Antiapoptotic Good Guys? |
|---|
|
|
|---|
In the study by Yue et al,1 the authors concluded that ERK1/ERK2 is important for myocyte survival in ischemic myocardium based on the effect of the MEK-1 inhibitor PD98059. However, the use of PD98059 as a selective MEK1/MEK2 inhibitor is not as safe as previously thought. Recently, this compound was found to inhibit the activation of BMK1 as well as ERK.22 MEK5 and BMK1 are highly expressed in cardiac myocytes.16 Importantly, BMK1 has also been proposed to be antiapoptotic based on results of MEK5 inhibition.23 MEK5-dependent BMK1 activation results in the phosphorylation of MEF2A and MEF2C, transcription factors that belong to the myocyte enhancer factor-2 (MEF2) family,24 which are important regulators of cardiac gene expression. Because BMK1 can also be activated in the ischemic myocardium,6 it will be necessary to evaluate the role of this MAP kinase in PD98059-induced survival.
| Apoptosis, Necrosis, and Cardiac Function |
|---|
|
|
|---|
The present study challenges this concept because Yue et
al1 showed significant improvement of cardiac function
after global ischemia within only 1 hour of reperfusion using
SB203580, a p38 inhibitor. In a similar study the authors
also found that apoptosis could be detected after only 1 hour
of reperfusion, and this was reversed by SB203580.27 These
data would indicate that the improvement of cardiac function is
directly correlated with the prevention of apoptosis. However,
SB203580 also reduced infarction so that p38 may have other effects on
cardiac function unrelated to apoptosis. We propose that the
posttranslational effects of MAP kinases, such as
phosphorylation of NHE-1 and BAD, contribute to the
protective effects in early cardiac function recovery, perhaps to a
greater extent than alternations in gene expression and
apoptosis (Figure
).
| Footnotes |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
P. S. Wolf, H. E. Merry, A. S. Farivar, A. S. McCourtie, and M. S. Mulligan Stress-activated protein kinase inhibition to ameliorate lung ischemia reperfusion injury J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 656 - 665. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Morisco, C. Marrone, V. Trimarco, S. Crispo, M. G. Monti, J. Sadoshima, and B. Trimarco Insulin resistance affects the cytoprotective effect of insulin in cardiomyocytes through an impairment of MAPK phosphatase-1 expression Cardiovasc Res, December 1, 2007; 76(3): 453 - 464. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Wall, J. Wei, M. Ly, P. Belmont, J. J. Martindale, D. Tran, J. Sun, W. J. Chen, W. Yu, P. Oeller, et al. Alterations in oxidative phosphorylation complex proteins in the hearts of transgenic mice that overexpress the p38 MAP kinase activator, MAP kinase kinase 6 Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2462 - H2472. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. C. Weber, J. Stursberg, N. M. Wirthle, O. Toma, W. Schlack, and B. Preckel Xenon preconditioning differently regulates p44/42 MAPK (ERK 1/2) and p46/54 MAPK (JNK 1/2 and 3) in vivo Br. J. Anaesth., September 1, 2006; 97(3): 298 - 306. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. K. Das and N. Maulik Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol. Interv., February 1, 2006; 6(1): 36 - 47. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-F. Su, A. Samsamshariat, J. Fu, Y.-X. Shan, Y.-H. Chen, D. Piomelli, and P. H. Wang Oleylethanolamide Activates Ras-Erk Pathway and Improves Myocardial Function in Doxorubicin-Induced Heart Failure Endocrinology, February 1, 2006; 147(2): 827 - 834. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Okada, H. Otani, Y. Wu, S. Kyoi, C. Enoki, H. Fujiwara, T. Sumida, R. Hattori, and H. Imamura Role of F-actin organization in p38 MAP kinase-mediated apoptosis and necrosis in neonatal rat cardiomyocytes subjected to simulated ischemia and reoxygenation Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2310 - H2318. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Sumida, H. Otani, S. Kyoi, T. Okada, H. Fujiwara, Y. Nakao, M. Kido, and H. Imamura Temporary blockade of contractility during reperfusion elicits a cardioprotective effect of the p38 MAP kinase inhibitor SB-203580 Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2726 - H2734. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Martindale, J. A. Wall, D. M. Martinez-Longoria, P. Aryal, H. A. Rockman, Y. Guo, R. Bolli, and C. C. Glembotski Overexpression of Mitogen-activated Protein Kinase Kinase 6 in the Heart Improves Functional Recovery from Ischemia in Vitro and Protects against Myocardial Infarction in Vivo J. Biol. Chem., January 7, 2005; 280(1): 669 - 676. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.-G. Cho, M. R. Mulloy, P. A. Chang, M. D. Johnson, A. S. Aharon, T. A. Robison, T. L. Buckles, D. W. Byrne, and D. C. Drinkwater Jr Blockade of the extracellular signal-regulated kinase pathway by U0126 attenuates neuronal damage following circulatory arrest J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1033 - 1040. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Force, K. Kuida, M. Namchuk, K. Parang, and J. M. Kyriakis Inhibitors of Protein Kinase Signaling Pathways: Emerging Therapies for Cardiovascular Disease Circulation, March 16, 2004; 109(10): 1196 - 1205. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Chen, R. Rajashree, Q. Liu, and P. Hofmann Acute p38 MAPK activation decreases force development in ventricular myocytes Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2578 - H2586. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Souza, R. Guabiraba, V. Pinho, A. Bristow, S. Poole, and M. M. Teixeira IL-1-Driven Endogenous IL-10 Production Protects Against the Systemic and Local Acute Inflammatory Response Following Intestinal Reperfusion Injury J. Immunol., May 1, 2003; 170(9): 4759 - 4766. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Regan, M. Broad, A. M. Byford, A. R. Lankford, R. J. Cerniway, M. W. Mayo, and G. P. Matherne A1 adenosine receptor overexpression attenuates ischemia-reperfusion-induced apoptosis and caspase 3 activity Am J Physiol Heart Circ Physiol, March 1, 2003; 284(3): H859 - H866. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Pye, F. Ardeshirpour, A. McCain, D. A. Bellinger, E. Merricks, J. Adams, P. J. Elliott, C. Pien, T. H. Fischer, A. S. Baldwin Jr., et al. Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury Am J Physiol Heart Circ Physiol, March 1, 2003; 284(3): H919 - H926. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ogita, K. Node, H. Asanuma, S. Sanada, Y. Liao, S. Takashima, M. Asakura, H. Mori, Y. Shinozaki, M. Hori, et al. Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart J. Am. Coll. Cardiol., September 4, 2002; 40(5): 998 - 1005. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Takeishi, Q. Huang, J.-i. Abe, W. Che, J.-D. Lee, H. Kawakatsu, B. D Hoit, Bradford.C Berk, and R. A Walsh Activation of mitogen-activated protein kinases and p90 ribosomal S6 kinase in failing human hearts with dilated cardiomyopathy Cardiovasc Res, January 1, 2002; 53(1): 131 - 137. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Hattori, H. Otani, T. Uchiyama, H. Imamura, J. Cui, N. Maulik, G. A. Cordis, L. Zhu, and D. K. Das Src tyrosine kinase is the trigger but not the mediator of ischemic preconditioning Am J Physiol Heart Circ Physiol, September 1, 2001; 281(3): H1066 - H1074. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Martin, M. Avkiran, R. A. Quinlan, P. Cohen, and M. S. Marber Antiischemic Effects of SB203580 Are Mediated Through the Inhibition of p38{alpha} Mitogen-Activated Protein Kinase: Evidence From Ectopic Expression of an Inhibition-Resistant Kinase Circ. Res., October 26, 2001; 89(9): 750 - 752. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |